| 1 |
32809070 | Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. | 2021 Jan |
1 |
| 2 |
33441417 | Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). | 2021 Jan |
2 |
| 3 |
33850463 | Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System. | 2021 |
1 |
| 4 |
33952821 | Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter. | 2021 |
2 |
| 5 |
34287770 | DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020. | 2021 Nov |
1 |
| 6 |
34384428 | Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors. | 2021 Aug 12 |
1 |
| 7 |
34484112 | Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. | 2021 |
2 |
| 8 |
34616361 | Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes. | 2021 |
1 |
| 9 |
34774622 | Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease. | 2021 Dec 15 |
1 |
| 10 |
32179246 | Alogliptin inhibits IL-1β-induced inflammatory response in fibroblast-like synoviocytes. | 2020 Jun |
2 |
| 11 |
32317005 | Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus. | 2020 Apr 21 |
2 |
| 12 |
32493335 | Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. | 2020 Jun 4 |
1 |
| 13 |
32588538 | Spectrofluorometric determination of alogliptin an antidiabetic drug in pure and tablet form using fluorescamine, a fluorogenic agent: application to content uniformity test. | 2020 Nov |
1 |
| 14 |
32655736 | Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study. | 2020 Jul |
2 |
| 15 |
30156056 | Effects of metformin and alogliptin on body composition in people with type 2 diabetes. | 2019 May |
1 |
| 16 |
30242726 | The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. | 2019 Mar |
1 |
| 17 |
30318179 | Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk. | 2019 Jan |
1 |
| 18 |
30654307 | Protective effects of alogliptin against TNF-α-induced degradation of extracellular matrix in human chondrocytes. | 2019 Mar |
2 |
| 19 |
30701000 | Investigation of a Dipeptidyl Peptidase-4 Inhibitor/Thiazolidinedione Combination Drug for Patients With Type 2 Diabetes and Poor Glycemic Control: Difficulty With Patient Enrollment. | 2019 Feb |
1 |
| 20 |
31018682 | Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial? | 2019 Jul |
1 |
| 21 |
31045223 | Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus. | 2019 Jun 11 |
1 |
| 22 |
31264097 | Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting. | 2019 Aug |
1 |
| 23 |
31275243 | DPP-4 Inhibition and the Path to Clinical Proof. | 2019 |
1 |
| 24 |
31654243 | Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus. | 2019 Nov |
1 |
| 25 |
32734188 | Alogliptin-Induced Minimal Change Nephrotic Syndrome and Interstitial Nephritis. | 2019 Mar-Apr |
1 |
| 26 |
29264712 | Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis. | 2018 Feb |
2 |
| 27 |
29270818 | The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. | 2018 May |
2 |
| 28 |
29330812 | Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial. | 2018 Feb |
1 |
| 29 |
29359260 | Clinical impact of oral antidiabetic medications in heart failure patients. | 2018 May |
1 |
| 30 |
29581078 | Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. | 2018 Jul |
1 |
| 31 |
29652078 | Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. | 2018 Aug |
1 |
| 32 |
29679391 | Cardiovascular effects of sitagliptin - An anti-diabetes medicine. | 2018 Jul |
1 |
| 33 |
29769203 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. | 2018 May 16 |
1 |
| 34 |
30345140 | Development and Validation of an HPLC Method for Determination of Antidiabetic Drug Alogliptin Benzoate in Bulk and Tablets. | 2018 |
1 |
| 35 |
33693068 | Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study. | 2018 Dec 11 |
1 |
| 36 |
27236239 | Effects of alogliptin on fractional flow reserve evaluated by coronary computed tomography angiography in patients with type 2 diabetes: Rationale and design of the TRACT study. | 2017 Mar |
1 |
| 37 |
27999883 | The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. | 2017 Mar |
2 |
| 38 |
28275958 | Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. | 2017 Apr |
3 |
| 39 |
28323503 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. | 2017 Nov |
5 |
| 40 |
28804210 | Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1. | 2017 |
1 |
| 41 |
28932239 | Computational Analysis of Gynura bicolor Bioactive Compounds as Dipeptidyl Peptidase-IV Inhibitor. | 2017 |
1 |
| 42 |
30603324 | Effects of alogliptin on the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus. | 2017 Jun |
1 |
| 43 |
26125284 | The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes. | 2016 Jan |
2 |
| 44 |
26607297 | Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. | 2016 |
2 |
| 45 |
26628419 | Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). | 2016 Jan |
1 |
| 46 |
26824365 | Novel Therapeutic Approaches in Diabetes. | 2016 |
1 |
| 47 |
27190600 | Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. | 2016 May 12 |
1 |
| 48 |
27480840 | Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. | 2016 Sep |
2 |
| 49 |
27573605 | Inhibition of DPP-4 by alogliptin improves coronary flow reserve and left ventricular systolic function evaluated by phase contrast cine magnetic resonance imaging in patients with type 2 diabetes and coronary artery disease. | 2016 Nov 15 |
4 |
| 50 |
27832184 | Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study. | 2016 |
1 |